Skip to main content
. 2021 Aug 16;12:731546. doi: 10.3389/fimmu.2021.731546

Figure 3.

Figure 3

Network meta-analysis composed of SICI- or DICI-based treatments and CT. (A) Pooled hazard ratio (HR) [95% CrIs (credible intervals)] for overall survival (OS) and progression-free survival (PFS) in the overall population. (B) Pooled odds ratio (OR) (95% CrIs) for objective response rate (ORR) and adverse events of grade 3 or higher (≥3AEs) in the overall population. (C) Pooled HR (95% CrIs) for OS of squamous and non-squamous subgroups. (D) Pooled HR (95% CrIs) for OS of PD-L1 <1% and PD-L1 ≥1% subgroups. (E) Pooled HR (95% CrIs) for OS of PD-L1 1%–49% and PD-L1 ≥50% subgroups. (F) Pooled HR (95% CrIs) for OS of high TMB and low TMB subgroups. Data in each cell are HR or OR (95% CrIs) for the comparison of upper row-defining treatment vs. lower row-defining treatment. HR less than 1 and OR more than 1 favor upper-row treatment. Significant results are highlighted in red and bold. SICI-based, treatments including single immune checkpoint inhibitor; DICI-based, treatment including double immune checkpoint inhibitors; CT, chemotherapy.